Alto Neuroscience (Alto Neuroscience) Change In Receivables : $0.01 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Change In Receivables?

Alto Neuroscience's change in receivables for the quarter that ended in Mar. 2024 was $0.01 Mil. It means Alto Neuroscience's Accounts Receivable declined by $0.01 Mil from Dec. 2023 to Mar. 2024 .

Alto Neuroscience's change in receivables for the fiscal year that ended in Dec. 2023 was $0.33 Mil. It means Alto Neuroscience's Accounts Receivable declined by $0.33 Mil from Dec. 2022 to Dec. 2023 .

Alto Neuroscience's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alto Neuroscience's liquidation value for the three months ended in Mar. 2024 was $189.08 Mil.

Alto Neuroscience Change In Receivables Historical Data

The historical data trend for Alto Neuroscience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Change In Receivables Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

-1.29

1.16

0.33

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial			1.02	-0.04	-	-	0.01

Alto Neuroscience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

Alto Neuroscience (NYSE:ANRO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alto Neuroscience's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Alto Neuroscience's accounts receivable are only considered to be worth 75% of book value:

Alto Neuroscience's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	205.895	-	16.818	+	0.75 * 0	+	0.5 * 0
=	189.08

Alto Neuroscience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024